ABILIFY MAINTENA 300 mg, powder and solvent for injectable suspension with extended release bottle, 2 ml + 3 needles
Active ingredients: Aripiprazole
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 ml + 3 needlesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ABILIFY MAINTENA 300 mg, poudre et solvant pour suspension injectable à libération prolongée
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon en verre de 300 mg - 1 flacon en verre de 2 mL + 1 seringue avec aiguille préfixée + 1 seringue jetable avec embout Luer Lock + 1 adaptateur de flacon + 3 aiguilles (25, 38 et 50 mm)
- Marketing authorisation holder
- OTSUKA PHARMACEUTICAL NETHERLANDS (PAYS BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Jan 2015
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68729480CIP72772184CIP133400927721847Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ARIPIPRAZOLEpoudre | 300 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.